TrialJAMA oncology2020

Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial.

Jonathan D Schoenfeld et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.